Large-vessel involvement in ANCA-associated vasculitis: A multicenter case-control study.

ANCA associated vasculitis Aorta Large vessel involvement Neurological involvement

Journal

Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053

Informations de publication

Date de publication:
21 May 2024
Historique:
received: 22 01 2024
revised: 08 04 2024
accepted: 15 04 2024
medline: 30 5 2024
pubmed: 30 5 2024
entrez: 29 5 2024
Statut: aheadofprint

Résumé

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) primarily affects small vessels. Large-vessel involvement (LVI) is rare. We aimed to describe the characteristics of LVI, to identify associated risk factors, and to describe its therapeutic management. This multicenter case-control (1:2) study included patients with AAV according to the ACR/EULAR classification and LVI as defined by the Chapel Hill nomenclature, together with controls matched for age, sex, and AAV type. We included 26 patients, 15 (58 %) of whom were men, with a mean age of 56.0 ± 17.1 years. The patients had granulomatosis with polyangiitis (n = 20), or microscopic polyangiitis (n = 6). The affected vessels included the aorta (n = 18; 69 %) supra-aortic trunks (n = 9; 35 %), lower-limb arteries (n = 5; 19 %), mesenteric arteries (n = 5; 19 %), renal arteries (n = 4; 15 %), and upper-limb arteries (n = 2; 8 %). Imaging showed wall thickening (n = 10; 38 %), perivascular inflammation (n = 8; 31 %), aneurysms (n = 5; 19 %), and stenosis (n = 4; 15 %). Comparisons with the control group revealed that LVI was significantly associated with neurological manifestations (OR=3.23 [95 % CI: 1.11-10.01, p = 0.03]), but not with cardiovascular risk factors (OR=0.70 [95 % CI: 0.23-2.21, p = 0.60]), or AAV relapse (OR=2.01 [95 % CI: 0.70-5.88, p = 0.16]). All patients received corticosteroids, in combination with an immunosuppressant in 24 (92 %), mostly cyclophosphamide (n = 10, 38 %) or rituximab (n = 9, 35 %). Regardless of distinctions based on vessel size, clinicians should consider LVI as a potential manifestation of AAV, with the aorta commonly affected. The risk of developing LVI appears to be greater for clinical phenotypes of AAV with neurological involvement. Standard AAV treatment can be used to manage LVI.

Identifiants

pubmed: 38810568
pii: S0049-0172(24)00115-X
doi: 10.1016/j.semarthrit.2024.152475
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

152475

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

V Monghal (V)

Médecine Interne, Centre Hospitalier Universitaire Gabriel-Montpied, 63000 Clermont-Ferrand, France.

X Puéchal (X)

National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP). Centre, Université Paris Cité, Paris, France.

P Smets (P)

Médecine Interne, Centre Hospitalier Universitaire Gabriel-Montpied, 63000 Clermont-Ferrand, France.

F Vandergheynst (F)

General Internal Medicine Department, Erasme University Hospital, Brussels, Belgium.

M Michel (M)

Centre de Référence des Cytopénies Auto-Immunes de l'Adulte, Service de Médecine Interne, CHU Henri Mondor, AP-HP, Université Paris-Est Créteil, Créteil, France.

E Diot (E)

Service de Médecine Interne Immunologie Clinique, CHU de Tours, F-37032 Tours, France.

Y Ramdani (Y)

Service de Médecine Interne Immunologie Clinique, CHU de Tours, F-37032 Tours, France.

T Moulinet (T)

Systemic and Autoimmune Rare Diseases, Nancy University Hospital, UMR 7365, IMoPA, Lorraine University, CNRS, Vandoeuvre-lès-Nancy, France.

R Dhote (R)

Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris (APHP), Avicenne Hospital, Paris, France.

A Hautcoeur (A)

Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris (APHP), Avicenne Hospital, Paris, France.

C Lelubre (C)

Department of Internal Medicine, CHU-Charleroi Marie-Curie, 6042 Charleroi, Belgium.

S Dominique (S)

CHU Rouen, Department of Pulmonology, F-76000 Rouen, France.

L Lebourg (L)

Department of Nephrology, Kidney Transplantation and Hemodialysis, Rouen University Hospital, Rouen, France.

S Melboucy (S)

Service de médecine interne et polyvalente, centre hospitalier de Saint-Quentin, 1, avenue Michel de l'Hospital, 02100, Saint-Quentin, France.

N Wauters (N)

General Internal Medicine Department, Erasme University Hospital, Brussels, Belgium.

A Carlotti (A)

Department of Pathology, Assistance Publique - Hôpitaux de Paris, Cochin Hospital, 75014, Paris, France.

F Cachin (F)

Service de Médecine Nucléaire, Centre Jean PERRIN, Clermont-Ferrand, France.

M Ebbo (M)

Département de Medecine Interne, CHU Timone, AP-HM, Aix Marseille Université, France.

N Jourde-Chiche (N)

Aix-Marseille Université, Faculté des Sciences Médicales et Paramédicales, C2VN, INRA 1260, INSERM 1263, AP-HM Hôpital de la Conception, Centre de Néphrologie et Transplantation Rénale, Marseille, France.

Michele Iudici (M)

National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP). Centre, Université Paris Cité, Paris, France.

O Aumaitre (O)

Médecine Interne, Centre Hospitalier Universitaire Gabriel-Montpied, 63000 Clermont-Ferrand, France; Université Clermont Auvergne Inserm U1071, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), USC-INRA 2018, Clermont-Ferrand, France.

M Andre (M)

Médecine Interne, Centre Hospitalier Universitaire Gabriel-Montpied, 63000 Clermont-Ferrand, France; Université Clermont Auvergne Inserm U1071, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), USC-INRA 2018, Clermont-Ferrand, France.

B Terrier (B)

National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP). Centre, Université Paris Cité, Paris, France.

L Trefond (L)

Médecine Interne, Centre Hospitalier Universitaire Gabriel-Montpied, 63000 Clermont-Ferrand, France; Université Clermont Auvergne Inserm U1071, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), USC-INRA 2018, Clermont-Ferrand, France. Electronic address: ltrefond@chu-clermontferrand.fr.

Classifications MeSH